Variable
|
All
|
Underweight
|
Normal weight
|
Overweight/obese
|
P value*
|
---|
Total
|
819
|
168
|
431
|
220
| |
Age (years)
|
0.043
|
<45
|
419 (51.2)
|
97 (57.7)
|
223 (51.7)
|
99 (45.0)
| |
≥45
|
400 (48.8)
|
71 (42.3)
|
208 (48.3)
|
121 (55.0)
| |
Sex
|
0.688
|
Men
|
681 (83.2)
|
139 (82.7)
|
355 (82.4)
|
187 (85.0)
| |
Women
|
138 (16.8)
|
29 (17.3)
|
76 (17.6)
|
33 (15.0)
| |
UICC T category
|
0.504
|
T1–2
|
369 (45.1)
|
76 (45.2)
|
201 (46.6)
|
92 (41.8)
| |
T3–4
|
450 (54.9)
|
92 (54.8)
|
230 (53.4)
|
128 (58.2)
| |
UICC N category
|
0.221
|
N0–1
|
417 (50.9)
|
89 (53.0)
|
227 (52.7)
|
101 (45.9)
| |
N2–3
|
402 (49.1)
|
79 (47.0)
|
204 (47.3)
|
119 (54.1)
| |
Metastasis onset
|
<0.001
|
Synchronous
|
272 (33.2)
|
42 (25.0)
|
135 (31.3)
|
95 (43.2)
| |
Metachronous
|
547 (66.8)
|
126 (75.0)
|
296 (68.7)
|
125 (56.8)
| |
Lung metastasis
|
0.709
|
Absent
|
469 (57.3)
|
96 (57.1)
|
242 (56.1)
|
131 (59.5)
| |
Present
|
350 (42.7)
|
72 (42.9)
|
189 (43.9)
|
89 (40.5)
| |
Liver metastasis
|
0.201
|
Absent
|
574 (70.1)
|
118 (70.2)
|
292 (67.7)
|
164 (74.5)
| |
Present
|
245 (29.9)
|
50 (29.8)
|
139 (32.3)
|
56 (25.5)
| |
Bone metastasis
|
0.032
|
Absent
|
382 (46.6)
|
67 (39.9)
|
219 (50.8)
|
96 (43.6)
| |
Present
|
437 (53.4)
|
101 (60.1)
|
212 (49.2)
|
124 (56.4)
| |
Solitary lesion
|
0.010
|
No
|
701 (85.6)
|
155 (92.3)
|
356 (82.6)
|
190 (86.4)
| |
Yes
|
118 (14.4)
|
13 (7.7)
|
75 (17.4)
|
30 (13.6)
| |
Number of involved sites
|
0.592
|
One
|
545 (66.5)
|
107 (63.7)
|
287 (66.6)
|
151 (68.6)
| |
Two or more
|
274 (33.5)
|
61 (36.3)
|
144 (33.4)
|
69 (31.4)
| |
Treatment modality
|
0.322
|
CT
|
607 (74.1)
|
132 (78.6)
|
313 (72.6)
|
162 (73.6)
| |
CT + LT
|
212 (25.9)
|
36 (21.4)
|
118 (27.4)
|
58 (26.4)
| |
- All values are presented as the number of cases followed by percentage in the parentheses
-
BMI body mass index; UICC Union of International Cancer Control; CT chemotherapy; LT local therapy
- * P values were computed excluding patients without information in the corresponding variable